Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers

S. Veneroni, N. Zaffaroni, M. G. Daidone, E. Benini, R. Villa, R. Silvestrini

Research output: Contribution to journalArticle

Abstract

The expression of P-glycoprotein (P-gp) was studied by immunocytohistochemistry, using the C219 monoclonal antibody, in 39 locally advanced breast cancers and 20 ovarian cancers from previously untreated patients. P-gp was expressed in 46 and 35% of breast and ovarian tumours, respectively. A significant association was observed in both tumour types between P-gp expression and in vitro resistance to doxorubicin. We also observed a higher clinical response rate to doxorubicin ± vincristine in patients with breast cancers not expressing P-gp. Conversely, no correlation was found between P-gp expression and in vitro resistance to cisplatin or in vivo response to cisplatin ± cyclophosphamide treatment in ovarian cancers. Our results support the relevance of P-gp expression as a specific indicator of resistance to certain drugs, such as doxorubicin and vincrinstine, involved in the phenomenon of multidrug resistance in breast and ovarian cancer cells.

Original languageEnglish
Pages (from-to)1002-1007
Number of pages6
JournalEuropean Journal of Cancer
Volume30
Issue number7
DOIs
Publication statusPublished - 1994

Keywords

  • breast cancer
  • chemosensitivity assays
  • doxorubicin
  • immunocytohistochemistry
  • multidrug resistance
  • ovarian cancer
  • P-glycoprotein

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers'. Together they form a unique fingerprint.

Cite this